Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors
出版年份 2019 全文链接
标题
Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors
作者
关键词
Lanreotide, Neuroendocrine tumor, Prognostic factor, RECIST, Tumor growth rate
出版物
BMC CANCER
Volume 19, Issue 1, Pages -
出版商
Springer Nature
发表日期
2019-01-14
DOI
10.1186/s12885-018-5257-x
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors
- (2017) Tetsuhide Ito et al. INVESTIGATIONAL NEW DRUGS
- Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms
- (2017) Günter Klöppel et al. VIRCHOWS ARCHIV
- Correlation of Ki-67 indices from biopsy and resection specimens of neuroendocrine tumours
- (2017) J Barnes et al. ANNALS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND
- Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study
- (2016) Martyn E Caplin et al. ENDOCRINE-RELATED CANCER
- Pitfalls in RECIST Data Extraction for Clinical Trials
- (2015) Richard G. Abramson et al. ACADEMIC RADIOLOGY
- O-016Exploratory analysis of tumor growth rate in patients with advanced gastrointestinal stromal tumors (GIST) treated with regorafenib in the GRID phase 3 trial
- (2015) C. Kappeler et al. ANNALS OF ONCOLOGY
- Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma
- (2015) Roberto Iacovelli et al. EUROPEAN UROLOGY
- The assessment of Ki-67 as a prognostic marker in neuroendocrine tumours: a systematic review and meta-analysis
- (2015) Sebastian Richards-Taylor et al. JOURNAL OF CLINICAL PATHOLOGY
- Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
- (2014) Martyn E. Caplin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Response Classification Based on a Minimal Model of Glioblastoma Growth Is Prognostic for Clinical Outcomes and Distinguishes Progression from Pseudoprogression
- (2013) M. L. Neal et al. CANCER RESEARCH
- Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials
- (2013) C. Ferte et al. CLINICAL CANCER RESEARCH
- The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: Results of a survey in the oncology community
- (2013) Yan Liu et al. EUROPEAN JOURNAL OF CANCER
- Tumor Growth Rate Provides Useful Information to Evaluate Sorafenib and Everolimus Treatment in Metastatic Renal Cell Carcinoma Patients: An Integrated Analysis of the TARGET and RECORD Phase 3 Trial Data
- (2013) Charles Ferté et al. EUROPEAN UROLOGY
- Discriminating Survival Outcomes in Patients with Glioblastoma Using a Simulation-Based, Patient-Specific Response Metric
- (2013) Maxwell Lewis Neal et al. PLoS One
- Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents
- (2012) C Le Tourneau et al. BRITISH JOURNAL OF CANCER
- RECIST: No Longer the Sharpest Tool in the Oncology Clinical Trials Toolbox--Point
- (2012) M. R. Sharma et al. CANCER RESEARCH
- Analyzing the Pivotal Trial That Compared Sunitinib and IFN- in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
- (2012) W. D. Stein et al. CLINICAL CANCER RESEARCH
- Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors
- (2012) Maxime Palazzo et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Therapeutic Monitoring of Gastroenteropancreatic Neuroendocrine Tumors: The Challenges Ahead
- (2012) Anders Sundin et al. NEUROENDOCRINOLOGY
- Tumour growth rates and RECIST criteria in early drug development
- (2011) Carlos Gomez-Roca et al. EUROPEAN JOURNAL OF CANCER
- Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy
- (2010) W. D. Stein et al. CLINICAL CANCER RESEARCH
- Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma
- (2009) Cosimo Durante et al. ENDOCRINE-RELATED CANCER
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now